A Breakthrough in Rare Disease Treatment
Recordati Industria Chimica e Farmaceutica SpA, a pharmaceutical company dedicated to researching, developing and marketing innovative treatments for rare diseases, has made a significant stride in the field. Their product, ISTURISA (osilodrostat), has been recognized for its expanded indication in treating endogenous hypercortisolism in Cushing’s syndrome.
This breakthrough is set to be showcased at the prestigious American Association of Clinical Endocrinology (AACE) Annual Meeting, where the company’s commitment to pushing boundaries in rare disease treatment will take center stage. ISTURISA’s expanded indication is a testament to the company’s focus on delivering innovative solutions to patients with complex conditions.
A New Era in Rare Disease Treatment
Recordati’s dedication to rare diseases has positioned the company as a leader in this specialized field. Their focus on developing and marketing treatments that address the unique needs of patients with rare conditions is expected to drive growth and positively impact the market. As a result, patients with Cushing’s syndrome and other rare diseases can look forward to more effective treatment options.
Key Highlights
- ISTURISA (osilodrostat) has been recognized for its expanded indication in treating endogenous hypercortisolism in Cushing’s syndrome
- The breakthrough will be showcased at the AACE Annual Meeting
- Recordati’s focus on rare diseases and innovative treatments is expected to drive growth and positively impact the market